Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: A Phase I study of ZYC101

Clinical Cancer Research

Volumn 8, Issue 5, 2002, Pages 1028-1037

  Klencke, Barbara ^a   Matijevic, Mark ^c   Urban, Robert G ^c   Lathey, Janet L ^c   Hedley, Mary Lynne ^c   Berry, Michael ^b   Thatcher, Joe ^b   Weinberg, Vivian ^b   Wilson, Jennifer ^b   Darragh, Teresa ^b   Jay, Naomi ^b   Da Costa, Maria ^b   Palefsky, Joel M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ZYCOS Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA A2 ANTIGEN; PLASMID DNA; POLYGLACTIN; UNCLASSIFIED DRUG; ZYC 101;

ADULT; AGED; ANUS CANCER; ANUS DISEASE; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DYSPLASIA; ENCAPSULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN CELL; HYPESTHESIA; IMMUNE RESPONSE; INJECTION PAIN; MALAISE; MALE; PHASE 1 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SQUAMOUS EPITHELIUM; SWEATING; VACCINATION; WART VIRUS;

ADULT; AGED; ANUS NEOPLASMS; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HLA-A2 ANTIGEN; HUMANS; MALE; MICROSPHERES; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAIN; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PEPTIDE FRAGMENTS; PLASMIDS; TIME FACTORS; TREATMENT OUTCOME; TUMOR VIRUS INFECTIONS; VACCINES, DNA;

EID: 0036091223     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Epidemiology of cervical human papillomavirus infections
2. Natural history and epidemiological features of genital HPV infection
3. Epidemiology of genital human papillomavirus infection
4. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective
5. Cancer of the uterine cervix
6. Role of the human papillomaviruses in human cancer
7. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18
8. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
9. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
10. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product
11. The epidemiology of cervical carcinogenesis
12. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
13. Human papillomavirus infection and anal cancer
14. Cancer statistics, 2000
15. Sexually transmitted infection as a cause of anal cancer
16. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer
17. Changing patterns of anal cancer incidence in the United States, 1940-1989
18. Association of cancer with AIDS-related immunosuppression in adults
19. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men
20. Anal cytology as a screening tool for anal squamous intraepithelial lesions
21. Colposcopic appearance of anal squamous intraepithelial lesions: Relationship to histopathology
22. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men
23. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus negative homosexual and bisexual men
24. Looking behind: Time for anal cancer screening
25. Healing after anal fistulotomy: Comparative study between HIV+ and HIV-patients
26. Surgery for anal lesions in HIV-infected patients
27. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides
28. Human papillomavirus immunology and vaccine prospects
29. Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma
30. Detection of T-helper responses, but not of human papillomavirus specific cytotoxic T-lymphocyte responses, after peptide vaccination of patients with cervical carcinoma
31. Protective antitumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T-lymphocyte epitopes in a string-of-beads fashion
32. A Phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV-16 positive
33. HPV vaccines for cervical cancer move toward clinic, encounter social issues
34. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 antisense RNA
35. Effects of human papillomavirus type 18-specific antisense oligonucleotides on the transformed phenotype of human carcinoma cell lines
36. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses
37. Human leukocyte antigen-A2.1 restricted candidate cytotoxic T-lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2
38. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins
39. Exposing the immunology of naked DNA vaccines
40. Virus-specific CD8+ T cells in primary and secondary influenza pneumonia
41. Evaluation of the INF-η ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood
42. Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the ELISPOT assay
43. A sensitive ELISPOT assay to detect low frequency human T lymphocytes
44. Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide
45. A recombinant vaccinia virus-based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals
46. ELISPOT assay for detection of peptide specific INF-γ secreting cells in rhesus macaques
47. Detection and enumeration of HIV-1-producing cells by ELISPOT (enzyme-linked immunospot) assay
48. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
49. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted, cell-mediated lysis
50. Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies